Developed under the auspices of the University of Glasgow supported by unrestricted educational grants from Pfizer Italia S.r.l. and R-Pharm CJSC
Interleukin-6 is proven to play a large role in the action of inflammatory disease through it's promotion of synovitis and joint destruction by stimulating neutrophil migration, osteoclast maturation and vascular endothelial growth factor (VEGF)-stimulated pannus proliferation. Because of this IL-6 blockade is a desirable therapeutic option in the treatment of RA with therapies both currently available and in development. This course looks to examine the history and science behind the targeting of IL-6 and help user's understand the benefits that IL-6 targeted therapies are bringing to the disease area.
By following this programme, you will be able to:
Professor Iain B. McInnes
Muirhead Professor of Medicine, Director of the Institute of Infection, Immunity and Inflammation,
Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.
Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and he is Associate Editor of Annals of Rheumatic Diseases and a member of the executive Editorial Board of the European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been widely recognised and has received many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the British Society of Rheumatology (BSR) Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of The European League Against Rheumatism (EULAR) Scientific Committee, he is now Liaison Officer to the American College of Rheumatology for EULAR. He was elected a fellow of the Royal Society of Edinburgh in 2008, and in 2012 was elected as a Fellow of the Academy of Medical Sciences.
|The Science of IL-6 in RA||
Professor Simon Jones
Associate Director for I&I Research,
Professor Simon Jones is currently Deputy Director for the Division of Infection and Immunity at the School of Medicine in Cardiff University where he leads the inflammation research group. He has a PhD in Biochemistry from Bristol University. Professor Jones has since developed a research programme focused on the cytokine pathways that determine balance between competent host defence and inflammation induced tissue damage. Studies explore the control of innate and adaptive immunity, and the contribution of stromal tissue in determining disease outcomes.
|The clinical impact of present and future IL-6 therapies in RA||
Professor Tsutomu Takeuchi
Professor of Rheumatology, Keio University School of Medicine,
Professor Tsutomu Takeuchi completed his medical education at Keio University School of Medicine and is currently Professor of Medicine in the Department of Internal Medicine at the same institution. His major research interests are molecular pathogenesis of systemic autoimmune diseases, targeted therapy in systemic autoimmune diseases, and prediction of therapeutic response. Professor Takeuchi has published more than 100 articles in peer-reviewed journals including Arthritis & Rheumatism, Annals of the Rheumatic Diseases, The Journal of Immunology, The Journal of Rheumatology, and The Journal of Clinical Investigation. Professor Takeuchi serves or has served as an editorial board member of the following journals: Rheumatology, Clinical Rheumatology, Clinical Immunology, and Modern Rheumatology. As a reviewer, he is currently serving for Nature Reviews of Immunology, The Lancet, Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Rheumatology, Arthritis Research & Therapy, The Journal of Rheumatology, The Journal of Clinical Rheumatology, APLAR Journal of Rhematology, Modern Rheumatology, The Journal of Immunology, European Journal of Immunology, International Immunology, and The American Journal of Pathology.
Date of preparation: February 2016